🏛️ Verified NIH Record • Updated 2025-11-03
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma (NCT04577300)
A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Stanford University
🩺 Plain-English Summary (8th-Grade Level)
To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.
Who can join: Review the eligibility criteria below.
Location: Byers Eye Institute at Stanford University — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Byers Eye Institute at Stanford University — Palo Alto, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Glaucoma
- Novel Markers for Detecting Early Progression of Glaucoma — Halifax, Nova Scotia
- Electrical Stimulation for the Treatment of Glaucoma — Palo Alto, California
- Visual Field Analysis With Artificial Intelligence — Alexandria, Virginia
- Anterior Segment Optical Coherence Tomography Microstent Positioning — Murray, Utah
- Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination — Santa Rosa de Copán,
- Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. — Glendale, Arizona
Explore by condition: All Glaucoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.